With increasing concerns about COVID-19 reinfection, Pfizer and the National Institutes of Health are discussing potential studies regarding a longer treatment period with the antiviral medication Paxlovid.
Why Pfizer May Be Holding Paxlovid Close to the ChestAntivirals, Bloomberg, Clinical Trials, COVID-19 Therapeutics, Drugs for Neglected Diseases Initiative (DNDi), FDA, Hospitalized COVID-19 Patients, Merck, Molnupiravir, Paxlovid, Pfizer, R&D, Symptoms: Coronavirus Disease 2019 (COVID-19), Therapeutics
Reportedly, Pfizer is holding the company’s COVID-19 antiviral therapy Paxlovid under tight control. This is a disappointment to numerous investigators who want to test the antiviral combination therapy with other drugs in case the virus develops resistance to the combo.
As U.S. COVID-19 cases rise, so does demand for antiviralsAntivirals, Apple, BNT162b2 (Pfizer and BioNTech), CDC, Connecticut, COVID-19 booster shots, COVID-19 cases, COVID-19 Therapeutics, COVID-19 Vaccines, Delaware, Department of Health and Human Services (HHS), Emergency Use Authorization (EUA), FDA, Health Officials, Hospitalized COVID-19 Patients, Maine, Massachusetts, Merck, Molnupiravir, New York, Northeast, Omicron (B.1.1.529) (South Africa), Omicron BA.2, Paxlovid, Pfizer, Regions, Reuters Tally, Rhode Island, Therapeutics, U.S. government, United States, White House
Rising COVID-19 cases are driving up the use of therapeutics, with Pfizer Inc.’s oral antiviral treatment Paxlovid seeing a 315 percent jump over the past four weeks, U.S. health officials said on May 17.
AstraZeneca boosts COVID portfolio with RQ Bio dealAcquisitions, AstraZeneca, Biotech, Business, Coronavirus Vaccines, COVID-19 Antibodies, COVID-19 shots, COVID-19 Therapeutic, COVID-19 therapeutic candidates, COVID-19 Therapeutics, COVID-19 Therapies, COVID-19 Vaccines, Evusheld (AstraZeneca), Evusheld (tixagevimab and cilgavimab; AstraZeneca), Licensing, R&D, Therapeutics, Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
AstraZeneca moved to bolster the company’s COVID-19 portfolio of antibodies on May 17 with a $157 million licensing deal for experimental therapies developed by newly launched biotech RQ Bio.
Shanghai targets June COVID lockdown exit as China economy slumpsChina, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Coronavirus Restrictions, Coronavirus surge, COVID guidelines, Covid-19 Airborne Transmission, COVID-19 booster shots, COVID-19 cases, Covid-19 fatality rate, COVID-19 Lockdown Measures, COVID-19 Prevention Measures, COVID-19 protocols, Covid-19 Quarantine, COVID-19 recommendations, COVID-19 risk, COVID-19 shots, COVID-19 Therapeutic, COVID-19 therapeutic candidates, COVID-19 Therapeutics, COVID-19 Therapies, COVID-19 transmission, COVID-19 vaccination rates, Covid-19 Variants, Mask-wearing, Pandemics, Shanghai, Therapeutics
Shanghai set out plans on May 16 for the end of a painful COVID-19 lockdown that has lasted more than six weeks, heavily bruising China’s economy, and for the return of more normal life from June 1.
Bristol Myers Squibb shared the news that the company’s Phase III clinical trial investigating the safety and efficacy of Opdivo and Yervoy combination therapy (NCT03036098) in patients with metastatic urothelial carcinoma failed to meet the predetermined primary endpoint. A posthoc analysis was shared by Synairgen suggesting that, despite SNG001 failing to meet the primary endpoint of patient recovery and subsequent hospital discharge in a Phase III study for patients hospitalized with COVID-19 who required supplemental oxygen treatment, they may benefit from receiving the treatment.
Leader Kim Jong Un ordered North Korea’s military to stabilize distribution of COVID-19 medicine in the capital, Pyongyang, in the battle against the country’s first confirmed outbreak of the disease, state media said.
U.S. will share COVID-19 vaccine technology, Biden tells global summitAntivirals, BNT162b2 (Pfizer and BioNTech), Congress, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Vaccines, COVID-19 Therapeutic, COVID-19 therapeutic candidates, COVID-19 Therapeutics, COVID-19 Therapies, COVID-19 Vaccines, Janssen COVID-19 Vaccine (J&J), Joe Biden, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Pandemic Preparedness, Pandemics, Summits, Therapeutics, U.S. government, United States, Vaxzevria (previously COVID-19 Vaccine AstraZeneca), WHO, World Bank, World Health Organization
The United States will share technologies used to make COVID-19 vaccines through the World Health Organization and is working to expand rapid testing and antiviral treatments for hard-to-reach populations, President Joe Biden said on May 12.
Generic drugmakers to sell Pfizer’s Paxlovid for $25 or less in low-income countriesClinton Health Access Initiative (CHAI), COVID-19 Therapeutic, COVID-19 Therapeutics, COVID-19 Therapies, Drug Pricing, Generic Substitution, Generics, Low-Income Countries, Medicines Patent Pool, Middle-Income Countries, Pfizer, Therapeutics, United Nations
Several generic drugmakers that will produce versions of Pfizer’s COVID-19 antiviral treatment Paxlovid agreed to sell the medicine in low-income and middle-income countries for $25 a course or less, the Clinton Health Access Initiative (CHAI) said on May 12.
Biden marks 1 million Americans dead from COVIDCongress, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19), Coronavirus Infections, Coronavirus Mutations, Coronavirus Restrictions, Coronavirus surge, COVID-19 booster shots, COVID-19 Deaths, COVID-19 Infections, COVID-19 shots, COVID-19 Therapeutic, COVID-19 therapeutic candidates, COVID-19 Therapeutics, COVID-19 Therapies, COVID-19 treatment pill, COVID-19 vaccination rates, Covid-19 Variants, Joe Biden, Pandemics, Reuters Tally, SARS-CoV-2 virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Summits, United States, White House, White House coronavirus task force
President Joe Biden on May 12 commemorated the death of 1 million people in the United States from COVID-19, marking what he called “a tragic milestone” and urging Americans to “remain vigilant” amid the ongoing pandemic.